Clinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damage
- Conditions
- Systemic lupus erythematosus
- Registration Number
- ITMCTR2000003055
- Lead Sponsor
- Zhejinag University of f Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) meet the diagnostic criteria of RA, activity period and abnormal heart function;
(2) between the ages of 18 and 60;
(3) if taking NSAIDs, the dose has been stable for at least 4 weeks; if not, it has been stable for at least 1 week;
(4) if you take MTX, you have been treated with MTX3 for at least 4 months, and the dose is fixed at 10mg/ week for at least 4 weeks.If you take LEF, you have been treated with leff for at least 3 months, and the dose is fixed at 10mg/ day for at least 4 weeks.
(5) if glucocorticoid is taken, the dose (compared with prednisone) must be less than 15mg/ day and has been used for at least 4 weeks;
(6) participate in the study voluntarily and sign the informed consent.
(1) intramuscular injection or intravenous drip of glucocorticoids within 4 weeks;
(2) das28-3 score > 5.1 (high activity);
(3) patients with other rheumatic diseases such as systemic lupus erythematosus, sjogren's syndrome and gout;
(4) pregnant or nursing women or those who plan to give birth in the near future;
(5) allergic to the test drugs;
(6) those who have participated in other clinical trials recently (within 1 month);
(7) mental patients and people without capacity for civil conduct.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SLEDAI;
- Secondary Outcome Measures
Name Time Method